Stage IV Breast Cancer Clinical Trial
Official title:
A 2X2X2 Factorial Randomized Phase III Trial Of Multimodality Therapy Comparing 4 Cycles Of Doxorubicin And Cyclophosphamide With Or Without Dexrazoxane (AC+/-Z) Followed By 12 Weeks Of Weekly Paclitaxel With Or Without Trastuzumab (T+/-H) Followed By Local Therapy Followed By 40 Weeks Of Weekly Trastuzumab Or None In Women With HER-2+ STAGE IIIA, IIIB OR REGIONAL STAGE IV BREAST CANCER
Randomized phase III trial to compare the effectiveness of combination chemotherapy, surgery, and radiation therapy with or without dexrazoxane and trastuzumab in treating women who have stage IIIA, stage IIIB or stage IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if chemotherapy combined with surgery and radiation therapy is more effective with or without dexrazoxane and trastuzumab in treating breast cancer
OBJECTIVES:
I. Determine the time to locoregional recurrence, time to completion of treatment, and
overall survival in women with HER-2+ stage IIIA or IIIB or regional stage IV breast cancer
treated with doxorubicin and cyclophosphamide with or without dexrazoxane, followed by
paclitaxel with or without trastuzumab (Herceptin), followed by surgery and radiotherapy
with or without trastuzumab.
II. Determine whether addition of trastuzumab to paclitaxel therapy improves response at 24
weeks of therapy in these patients.
III. Determine whether addition of trastuzumab to paclitaxel therapy increases the rate of
cardiotoxicity in these patients.
IV. Determine whether addition of dexrazoxane to doxorubicin and cyclophosphamide
compromises response in these patients.
V. Determine whether addition of dexrazoxane to doxorubicin and cyclophosphamide reduces the
rate of cardiotoxicity in these patients.
VI. Determine whether long-term trastuzumab after local therapy improves disease-free
survival in these patients.
VII. Determine whether long-term trastuzumab after local therapy increases the rate of
cardiotoxicity in these patients.
VIII. Determine the occurrence of any grade 3 or higher toxicity, second malignancies, acute
myelogenous leukemia, or myelodysplastic syndrome in patients treated with these regimens.
IX. Determine the eventual rate of breast conservation in those patients considered
candidates for breast conservation prior to neoadjuvant treatment.
X. Determine the clinical response after doxorubicin and cyclophosphamide with or without
dexrazoxane and the clinical/mammographic/ultrasound response after paclitaxel with or
without trastuzumab, compared to the pathologic response at definitive surgery in these
patients.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
according to stage (inflammatory vs noninflammatory inoperable stage III/ regional stage IV
vs operable stage III). Patients are randomized to 1 of 8 treatment arms.
Arm I: Patients receive dexrazoxane IV over 10-20 minutes, doxorubicin IV over 5-10 minutes,
and cyclophosphamide IV over 30 minutes on days 1, 22, 43, and 64. Patients receive
paclitaxel IV over 1 hour and trastuzumab (Herceptin) IV over 30-90 minutes on days 85, 92,
99, 106, 113, 120, 127, 134, 141, 148, 155, and 162. Approximately 1-2 weeks after
completion of neoadjuvant chemotherapy, patients undergo breast conservation surgery,
modified radical mastectomy, or mastectomy. Patients with unacceptable toxicity or
locoregional disease progression may undergo surgery prior to week 24 (i.e., completion of
neoadjuvant chemotherapy). Beginning 2-4 weeks after breast conservation surgery or 3-5
weeks after mastectomy, patients undergo radiotherapy daily 5 days a week for 6-8 weeks.
Patients receive long-term trastuzumab IV over 30-90 minutes weekly for 40 weeks beginning
on week 36 (day 254).
Arm II: Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I.
Patients receive paclitaxel (without trastuzumab) as in arm I. Patients undergo surgery and
radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
Arm III: Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I.
Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and
radiotherapy as in arm I. Patients undergo observation only for 40 weeks after completion of
radiotherapy.
Arm IV: Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I.
Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in
arm I. Patients undergo observation as in arm III.
Arm V: Patients receive doxorubicin and cyclophosphamide (without dexrazoxane) as in arm I.
Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and
radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
Arm VI: Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive
paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients
receive long-term trastuzumab as in arm I.
Arm VII: Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive
paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm
I. Patients undergo observation as in arm III.
Arm VIII: Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive
paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients
undergo observation as in arm III.
Treatment continues in all arms in the absence of distant disease progression. Beginning
within 12 weeks of completion of neoadjuvant chemotherapy, hormone receptor-positive
patients may receive oral tamoxifen daily for 5 years.
Patients are followed every 6 months for 5 years and then annually for 5 years.
PROJECTED ACCRUAL: A total of 396 patients will be accrued for this study within 4 years.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01987726 -
Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
|
||
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Terminated |
NCT01918306 -
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Terminated |
NCT01222377 -
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
N/A | |
Completed |
NCT00602043 -
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
|
Phase 2 | |
Completed |
NCT00100750 -
Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00244881 -
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
|
Phase 2 | |
Completed |
NCT00425672 -
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT00096109 -
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00096434 -
Sorafenib in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00057941 -
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT02892734 -
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03213041 -
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02015559 -
Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
|
Phase 2 | |
Completed |
NCT02728596 -
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
|
N/A | |
Completed |
NCT03364348 -
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
|
Phase 1 | |
Completed |
NCT02897375 -
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT01672684 -
Phase I: At-Home Support for Rural Women Using Group Video Calling
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 |